Table 3.
Multivariable analysis for patients characteristics, treatments and mutations in the complete cohort.
| Patients Characteristics | CR | OS | DFS | |||
|---|---|---|---|---|---|---|
| HR | p | HR | p | HR | p | |
| HSCT | - | - | 0.34 (0.19–0.60) | 0.0002 | 0.34 (0.19–0.60) | <0.0001 |
| Age > 60 | 0.43 (0.15–1.22) | 0.1049 | 1.37 (0.78–2.40) | 0.2661 | 0.89 (0.51–1.55) | 0.6864 |
| De novo | 2.17 (0.55–7.76) | 0.2460 | - | - | - | - |
| ECOG PS 2–3 | 0.26 (0.07–1) | 0.0398 | 1.09 (0.42–2.85) | 0.8559 | - | - |
| WBC count > 50 | - | - | 1.20 (0.67–2.14) | 0.5456 | 1.07 (0.63–1.82) | 0.8023 |
| NPM1 | 1.06 (0.33–3.3) | 0.9239 | 0.58 (0.32–1.06) | 0.0761 | 0.49 (0.28–0.88) | 0.0163 |
| FLT3-ITD | - | - | 2.76 (1.56–4.91) | 0.0005 | 2.81 (1.66–4.73) | 0.0001 |
| DNMT3A | - | - | - | - | 1.62 (0.95–2.77) | 0.0772 |
| TET2 | 0.4 (0.13–1.24) | 0.1048 | 0.74 (0.33–1.66) | 0.4715 | - | - |
| RUNX1 | 0.54 (0.15–2.03) | 0.3501 | 1.25 (0.60–2.61) | 0.5567 | 0.89 (0.43–1.87) | 0.7638 |
| CEBPA2 * | - | - | 0.20 (0.06–0.68) | 0.0097 | 0.17 (0.05–0.57) | 0.0040 |
| FLT3_PM | - | - | 0.65 (0.23–1.89) | 0.4325 | 0.65 (0.25–1.67) | 0.3731 |
| ASXL1 | 0.87 (0.19–4.63) | 0.8628 | 0.42 (0.16–1.08) | 0.0713 | - | - |
| PTPN11 | - | - | 0.60 (0.21–1.73) | 0.3450 | - | - |
| SRSF2 | 0.24 (0.06–0.95) | 0.0376 | - | - | - | - |
| STAG2 | 0.97 (0.18–6.65) | 0.9715 | - | - | - | - |
| SF3B1 | - | - | - | - | 1.02 (0.42–2.45) | 0.9663 |
| U2AF1 | - | - | 4.19 (1.72–10.23) | 0.0016 | 5.54 (2.25–13.66) | 0.0002 |
* CEBPA2 indicates the presence of a double mutation.